Colorectal cancer (CRC) is one of the most frequent cancers in the world with a very high mortality rate even after surgical resection, radio- and chemotherapy ([Cancer Research Campaign, 1999](#bib10){ref-type="other"}). It seems evident that CRC frequently follows and develops from adenomatous polyps ([Leslie *et al*, 2002](#bib26){ref-type="other"}). Several studies suggest that non-steroidal anti-inflammatory drugs (NSAIDS) such as selective cyclooxygenase-2 (COX2) inhibitors have an anti-neoplastic effect ([Giercksky, 2001](#bib19){ref-type="other"}; [Cho *et al*, 2007](#bib13){ref-type="other"}; [Saini *et al*, 2009](#bib32){ref-type="other"}).

Cyclooxygenase-2, one of the key enzymes of arachidone acid metabolism and prostaglandin synthesis, is described to be involved in the early stage of colorectal carcinogenesis. Cyclooxygenase-2 overexpression was shown in 85% of CRCs in proportion to normal tissue, and this expression alteration occurs in 50% of adenomas ([Eberhart *et al*, 1994](#bib14){ref-type="other"}). Cyclooxygenase-2 can be activated through several cancer-associated biological pathways, such as Wnt- and Ras-related ones ([Brown and DuBois, 2005](#bib8){ref-type="other"}). Pre-clinical studies suggest that the treatment of colorectal adenomas with selective COX2 inhibitors can contribute to the chemoprevention of CRC ([Brown and DuBois, 2005](#bib8){ref-type="other"}).

The lack of COX2 expression characterises most normal tissues, but its level rapidly increases under mitogens and cytokines, which results in the accumulation of prostanoids (such as PGE2) in neoplastic and inflamed tissues ([Eisinger *et al*, 2007](#bib15){ref-type="other"}). Elevated COX2 levels may lead to tumour development and expansion through activation of EGFR- and Tcf/Lef signal transduction pathways. Inhibition of apoptosis, interference with the immune system and facilitation of angiogenesis (vascular endothelial growth factor (VEGF) activation) and tumour invasion may also result from elevated PGE2 levels ([Grösch *et al*, 2006](#bib20){ref-type="other"}).

Selective COX2 inhibitors seem to reduce the risk of developing colon cancer through COX2-dependent and -independent mechanisms. N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide (NS398), a selective COX2 inhibitor, exerts its anti-carcinogenic effect by inducing apoptosis ([Li *et al*, 2001](#bib28){ref-type="other"}; [Nishikawa *et al*, 2004](#bib31){ref-type="other"}) and inhibiting cell cycle progression ([Hung *et al*, 2000](#bib24){ref-type="other"}; [Zhang and DuBois, 2001](#bib42){ref-type="other"}), angiogenesis ([Abdelrahim and Safe, 2005](#bib1){ref-type="other"}; [Huang *et al*, 2005](#bib23){ref-type="other"}) and metastasis ([Abiru *et al*, 2002](#bib2){ref-type="other"}; [Nishikawa *et al*, 2004](#bib31){ref-type="other"}; [Yao *et al*, 2004](#bib39){ref-type="other"}; [Chen *et al*, 2006](#bib12){ref-type="other"}; [Banu *et al*, 2007](#bib5){ref-type="other"}; [Leung *et al*, 2008](#bib27){ref-type="other"}). NS398 was reported to cause significant growth inhibition in HCA-7 colon carcinoma cells ([Zhang and DuBois, 2001](#bib42){ref-type="other"}). It inhibits PGE2 synthesis and arrests cell cycle in G1 phase by enhancing p27KIP1 expression ([Hung *et al*, 2000](#bib24){ref-type="other"}). NS398-dependent apoptosis in colon cancer cells occurs through a cytochrome *c*-dependent pathway ([Li *et al*, 2001](#bib28){ref-type="other"}). Reducing VEGF levels with NS398 treatment refers to its anti-angiogenic effect ([Abdelrahim and Safe, 2005](#bib1){ref-type="other"}; [Huang *et al*, 2005](#bib23){ref-type="other"}). Inhibitory effects of NS398 on cancer invasiveness and metastatic growth have been proven both *in vitro* in cell culture ([Abiru *et al*, 2002](#bib2){ref-type="other"}; [Yao *et al*, 2004](#bib39){ref-type="other"}; [Chen *et al*, 2006](#bib12){ref-type="other"}; [Banu *et al*, 2007](#bib5){ref-type="other"}; [Leung *et al*, 2008](#bib27){ref-type="other"}) and *in vivo* in animal model experiments ([Chen *et al*, 2006](#bib12){ref-type="other"}; [Leung *et al*, 2008](#bib27){ref-type="other"}). Therapeutic effects of NS398 can be exerted by downregulation of matrix metalloproteinase-2 expression ([Yao *et al*, 2004](#bib39){ref-type="other"}; [Leung *et al*, 2008](#bib27){ref-type="other"}), blocking of epidermal growth factor receptor transactivation ([Banu *et al*, 2007](#bib5){ref-type="other"}) or inhibition of HGF-induced invasiveness ([Abiru *et al*, 2002](#bib2){ref-type="other"}; [Chen *et al*, 2006](#bib12){ref-type="other"}). However, the complete molecular background of NS398 treatment on colon adenocarcinoma cells has not been analysed yet.

The aims of this study were to analyse the gene expression modulating effect of NS398 selective COX2 inhibitor on the HT29 colon adenocarcinoma cell line and to correlate this effect to the modulation in gene expression observed during normal-adenoma and normal-CRC transition when biopsy samples were analysed.

Materials and methods
=====================

Cell culture
------------

HT29 colon adenocarcinoma cells were cultured at 37°C with 5% CO~2~ in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO, USA) containing gentamycin and 10% FCS. In six-well plates, 300 000 cells per well were cultured for 1 day, and were then treated with 10, 25 and 100 *μ*[M]{.smallcaps} NS398 (Sigma-Aldrich, diluted in DMSO) for 72 h in FCS-free medium. 0.1% DMSO was used as control. Total RNA was extracted from three samples treated with 100 *μ*[M]{.smallcaps} NS398 and from three untreated controls for microarray analysis. In parallel, 40 000 cells per slide were cytocentrifuged and fixed for immunocytochemical analysis.

MTT cell proliferation assay
----------------------------

In 96-well plates, 5000 HT29 cells per well were maintained for 24 h in 100 *μ*l RPMI-1640 medium containing 10% FCS, after which, the cells were treated with 10, 25 and 100 *μ*[M]{.smallcaps} NS398 (Sigma-Aldrich, diluted in DMSO) for 48 or 72 h in FCS-free medium. A volume of 0.5 mg ml^−1^ of MTT (methylthiazolyldiphenyl-tetrazolium bromide, Sigma-Aldrich) was then added to each well, and the cells were incubated for 4 h at 37°C. The medium was carefully removed, and blue formazan -- spawned from MTT by the mitochondrial dehydrogenase enzyme system of cells -- was diluted in DMSO. Absorbance was measured at 570 nm using a Multiskan MS ELISA plate reader (Thermo Fisher Scientific Inc., Waltham, MA, USA).

Laser microdissection
---------------------

Samples were derived from surgically removed tissue from six patients with moderately differentiated, Dukes B stage, left-side CRC. In parallel, six adenoma specimens were collected. Paired control non-tumour tissues from patients were obtained from a clinically unaffected site near the resection end and were histologically normal. Tissue samples were immediately frozen in liquid nitrogen after surgery and were stored at −80°C until the cutting period. Frozen tissue was placed in a cryomold with Tissue Tek embedding medium on dry ice for 1 min. Frozen tissue specimens were cut in a series of 6-*μ*m-thick sections onto PALM membrane-mounted glass slides at −20°C. After cutting, the slides were taken into dry ice, and were stored at −80°C until microdissection for up to 48 h before staining and dissection. The frozen sections were fixed in ethanol series, and were stained using cresyl violet (Sigma-Aldrich). After staining the tissue, tumour and normal tissues were diagnosed by the pathologist. A total of 5000 epithelial cells were collected from each section using the PALM system (PALM, Bernried, Germany).

Microarray analysis
-------------------

Total RNA was extracted from HT29 cells using the RNeasy Mini Kit (Qiagen Inc., Germantown, MD, USA) and from LCM cells using the RNeasy Micro Kit (Qiagen Inc.), according to the manufacturer\'s instructions. The quantity and quality of isolated RNA were tested by measuring absorbance and capillary gel electrophoresis using the 2100Bioanalyzer and RNA 6000 Pico Kit (Agilent Inc., Santa Clara, CA, USA). Biotinylated cRNA probes were synthesised from 1 to 5 *μ*g total RNA and fragmented using the One-Cycle Target Labeling and Control Kit (<http://www.affymetrix.com/support/downloads/manuals/expression_s2_manual.pdf>), according to the Affymetrix description. In case of LCM samples, two-cycle T7-based linear amplification was performed according to instructions of the manufacturer (Affymetrix Inc., Santa Clara, CA, USA). A volume of 10 *μ*g of each fragmented cRNA sample was hybridised into HGU133 Plus2.0 array (Affymetrix) at 45°C for 16 h. Slides were washed and stained using Fluidics Station 450 and an antibody amplification staining method according to the manufacturer\'s instructions. Fluorescent signals were detected by a GeneChip Scanner 3000 (Affymetrix). Fifty-three microarrays from colonic biopsy samples (11 normal, 20 villous adenoma, 22 CRC) had been hybridised earlier, their data files were used in a previously published study using different comparisons ([Galamb *et al*, 2008a](#bib16){ref-type="other"}, [2008b](#bib17){ref-type="other"}, [2009](#bib18){ref-type="other"}) and are available in the Gene Expession Omnibus database (series accession numbers: [GSE4183](GSE4183) and [GSE10714](GSE10714)).

Statistical evaluation of mRNA expression profiles
--------------------------------------------------

### Pre-processing and quality control

Quality control analyses were performed according to the suggestions of The Tumour Analysis Best Practices Working Group ([Tumor Analysis Best Practices Working Group, 2004](#bib38){ref-type="other"}). Scanned images were inspected for artifacts; the percentage of present calls (\>25%) and control of RNA degradation were evaluated. On the basis of evaluation criteria, all biopsy and HT29 measurements fulfilled the minimal quality requirements. In case of HT29 experiments, the similarity of the 3-3 biological replicates was stated using the Euclidean distance method ([Supplementary Figure 1](#sup1){ref-type="other"}). Affymetrix expression arrays were pre-processed by gcRMA with quantile normalisation and median polish summarisation. Data sets are available in the Gene Expression Omnibus databank for further analysis (<http://www.ncbi.nlm.nih.gov/geo/>), series accession numbers: [GSE15799](GSE15799), [GSE15960](GSE15960), [GSE4183](GSE4183) and [GSE10714](GSE10714)).

### Further analyses

To identify differentially expressed features, significance analysis of microarrays (SAM) was used. The nearest shrunken centroid method (prediction analysis of microarrays=PAM) was applied for sample classification from gene expression data. Prediction analysis of microarrays uses soft thresholding to produce a shrunken centroid, which allows the selection of characteristic genes with high predictive potential ([Tibshirani *et al*, 2002](#bib37){ref-type="other"}). Pre-processing, data mining and statistical steps were performed using R-environment with Bioconductor libraries. Annotation and functional classification of discriminatory genes were performed using the Affymetrix NetAffx system.

Taqman RT--PCR
--------------

TaqMan real-time PCR was used to measure the expression of 12 selected genes using an Applied Biosystems Micro Fluidic Card System (Applied Biosystems, Foster City, CA, USA). The selected genes belonged to the PAM discriminatory genes between CRC and normal, and between adenoma and normal samples, and validated Taqman assays were available. The following commercially available Taqman Gene Expression Assays (Applied Biosystems) were applied: ABCA8 (Hs00200350_m1), TRPM6 (Hs00214306_m1), VWF (Hs00169795_m1), IL8 (Hs00174103_m1), LCN2 (Hs00194353_m1), CXCL1 (Hs00236937_m1), COL4A1 (Hs00266237_m1), MCAM (Hs00174838_m1), IL1RN (Hs00277299_m1), CXCL2 (Hs00236966_m1), DUOX2 (Hs00204187_m1) and SPP1 (Hs00167093_m1). Ribosomal RNA 18S (Hs99999901_s1) was used as reference. Using the Taqman Reverse Transcription Kit, 400 ng per sample of total RNA was reverse transcribed (Applied Biosystems). The quality of cDNA samples was checked by CK20/PBGD real-time PCR (F. Hoffmann-La Roche Ltd., Basel, Switzerland). Expression analysis of the selected genes was performed from 100 ng per sample cDNA template, using Taqman Low-Density Array for Gene Expression: Format 96a and Taqman Universal PCR Master Mix (Applied Biosystems). Measurements were determined using an ABI PRISM 7900HT Sequence Detection System as described in the products User Guide (<http://www.appliedbiosystems.com>). After enzyme activation at 95°C for 10 min, 40 PCR cycles were carried out (denaturation at 95°C for 15 s, annealing and extension at 60°C for 1 min). Data analysis was carried out using SDS 2.2 software, as described earlier ([Galamb *et al*, 2008a](#bib16){ref-type="other"}). Baseline calculation and CT determination by individual thresholds according to the exponential phase of individual PCR reactions were automatically performed by the software. Variation of CT values of the three technical replicates was evaluated and accepted if it was under 0.5 cycle. Assays with an ΔRn value (difference between normalised reporter emission (Rn) of the sample template reaction and Rn of an unreacted sample) significantly differing from the average ΔRn should be excluded from further analysis. Relative quantification of gene expression was performed and fold change values were calculated using the ΔΔCT method ([Livak and Schmittgen, 2001](#bib29){ref-type="other"}). The threshold cycle (CT) of the 18S ribosomal RNA endogenous control was used to normalise target gene expression (ΔCT) to correct for experimental variation. The extracted ΔCT values were grouped according to histological groups. Thereafter, Student\'s *t*-test was conducted to compare the expression values between groups.

HT29 immunocytochemistry
------------------------

For immunocytochemical analysis, 40 000 HT29 cells per slide were cytocentrifuged and fixed in aceton for 5 min, dried for 30 min at room temperature and stored at −20°C until staining. HT29 cells were immunolabelled using an anti-COX2 antibody and Novolink Polymer Detection System (Novocastra Laboratories Ltd., Newcastle upon Tyne, UK). Endogen peroxidase activity was neutralised by incubation for 30 min at room temperature in 0.5% hydrogen peroxide (in methanol). To reduce potential non-specific background, slides were treated with Protein Block reagent (Novocastra Laboratories Ltd.) for 5 min. After washing them twice in tris buffered saline for 5 min, the slides were incubated with rabbit monoclonal anti-human COX2 IgG (1:100, clone SP21, Thermo Fisher Scientific) for 1 h at room temperature. Antibodies were detected using the Novolink Polymer Detection System, followed by diaminodbenzidine substrate/chromogen (Novocastra). Haematoxylin co-staining was performed. The immunostained slides were digitalised using high-resolution MIRAX DESK instrument (Zeiss, Gottingen, Germany), and analysed with MIRAX Viewer version 1.11.43.0 and HistoQuant software (Zeiss). Total and COX2-positive cells (total cell number: approximately 1000) with × 32 magnification were counted in each sample. For statistical analysis, the *t*-test was performed to evaluate the difference of COX2-positive/total cell number ratios between NS398-treated and untreated control cells.

Western blot analysis
---------------------

HT29 colon adenocarcinoma cells were cultured for 1 day at 37°C with 5% CO~2~ in RPMI-1640 medium (Sigma-Aldrich) containing gentamycin and 10% FCS, and then treated with 25, 50 and 100 *μ*[M]{.smallcaps} NS398 (Sigma-Aldrich, diluted in DMSO) for 72 or 96 h in FCS-free medium. 0.1% DMSO was used as control. Soluble protein fractions were prepared from 1.5 × 10^6^ Triton X-100-treated cells in the presence of protease and phosphatase inhibitors, as described ([Alpert *et al*, 2006](#bib3){ref-type="other"}). Protein samples (25 *μ*g) were electrophoresed (10% SDS--PAGE). Western blot analysis of COX2 (rabbit anti-human polyclonal COX2 antibody, Code: RB-9072, 1 *μ*g ml^−1^, Thermo Fisher Scientific) was performed as previously described ([Tátrai *et al*, 2006](#bib36){ref-type="other"}). The ECL (Enhanced Chemiluminescent) technique (Dako, Glostrup, Denmark) and the Kodak Image Station 4000 MM instrument equipped with Molecular Imaging Software version 4.0 (Carestream Health Inc., Rochester, NY, USA) were used for visualisation and data evaluation.

Ethical consideration
---------------------

All routine colonic biopsy and surgical tissue specimens from patients were taken after informed consent and ethical permission was obtained for participation in the study.

Results
=======

Colorectal adenoma and cancer-related mRNA expression patterns
--------------------------------------------------------------

Using PAM, between adenoma and normal biopsy samples, 20 classifiers were identified, including overexpressed cadherin 3, KIAA1199, forkhead box Q1 and downregulated carbonic anhydrase 7, glucagon, somatostatin, Spi-B transcription factor, claudin 8, bestrophin 4, peptide YY (sensitivity: 100%, specificity: 100%) ([Table 1](#tbl1){ref-type="table"}). Normal and CRC biopsy samples could be distinguished using 38 discriminatory genes (sensitivity: 90.91%, specificity: 100%) ([Table 1](#tbl1){ref-type="table"}). In LCM experiments, 65% of adenoma-related gene expression changes originated from epithelial cells, whereas 53% of CRC-related markers were epithelium derived.

Validation of adenoma- and CRC-specific markers
-----------------------------------------------

All 12 measured genes showed a similar expression tendency than when detected by microarray analysis, and 9 of them correlated with the results obtained using Affymetrix microarrays at a significance of *P*\<0.05. The expression changes of the selected genes are summarised in [Table 2](#tbl2){ref-type="table"}.

Effects of NS398 treatment on gene expression in HT29 cells
-----------------------------------------------------------

In all, 1925 differentially expressed genes were identified between the NS398-treated and untreated control group using SAM at a significance of *P*\<0.05 ([Supplementary Table 1](#sup1){ref-type="other"}). A further feature selection criterion was the logFC (log fold change) value. Within the differentially expressed genes, 1156 at least two-fold-overexpressed genes were found with a logFC value higher than 1, whereas 769 at least two-fold downregulated genes were determined with a logFC value lower than −1. The expression of genes involved in cell proliferation and cell cycle regulation (such as overexpressed CDKN3, BTG2, TGFB1, CNOT8, KAT2B, RARRES3, CDKN2C, RARRES1, MAGED1, PPAP2A, MXD4, TENC1, SESN1, and downregulated CDCA4, VEGFA), intracellular signal transduction, transcription regulation, metabolic and transport processes and apoptosis (overexpressed CDKN2C, BIK, CASP6, TIA, DAPK3, and dowregulated ANXA1, CEBPB, CBX4) are mainly changed under NS398 treatment. However, the function of several differentially expressed transcripts is not known yet. The functional classification of genes is represented in [Figure 1](#fig1){ref-type="fig"}.

In correlation with the mRNA expression findings, significant dose-dependent cell proliferation inhibition was measured using MTT assay, which was carried out to optimise the treatment concentration of NS398 COX2 inhibitor.

Changes in colorectal adenoma and cancer-related mRNA expression patterns under NS398 treatment
-----------------------------------------------------------------------------------------------

Seventeen of these 20 genes changed in a reverse manner in HT29 colon adenocarcinoma cells under NS398 COX2 inhibitor treatment, 14 of them (including upregulated somatostatin, claudin 8, peptide YY, and downregulated cadherin 3, KIAA1199) at a significance of *P*\<0.05 ([Figure 2A](#fig2){ref-type="fig"}). The expression of 12 of the 38 CRC-related markers (such as carbonic anhydrase 7, interleukin 8, melanoma cell adhesion molecule) was changed in a reverse manner under NS398 treatment ([Figure 2B](#fig2){ref-type="fig"}).

HT29 immunocytochemistry and western blot results
-------------------------------------------------

Dose-dependent inhibition of COX2 protein expression was observed under NS398 treatment. COX2-positive cell/total cell ratio was 80.5% in untreated control samples, whereas it decreased to 77.0% under 10 *μ*[M]{.smallcaps}, to 61.2% under 25 *μ*[M]{.smallcaps} NS398 treatment. Further elevation of the NS398 dose (100 *μ*[M]{.smallcaps}) caused a significant decrease in the positive cell ratio (53.1%). Strong granular and/or diffuse cytoplasmatic immunostaining was detected in COX2-positive cells ([Figure 3A and B](#fig3){ref-type="fig"}). Western blot results showed correlation to the immunocytochemistry findings ([Figure 3C](#fig3){ref-type="fig"}). More considerable reduction in COX2 protein expression was detected after 96 h of NS398 treatment at 50 and 100 *μ*[M]{.smallcaps} concentrations.

Discussion
==========

It is a known fact that COX2 inhibitor treatment leads to a significant reduction in the number of colorectal polyps in patients with familial adenomatous polyposis ([Steinbach *et al*, 2000](#bib35){ref-type="other"}; [Higuchi *et al*, 2003](#bib22){ref-type="other"}). Selective COX2 inhibitors also seem to be effective for prevention of sporadic adenomatous polyps, as they significantly reduced the occurrence of colorectal adenomas within 3 years after polypectomy ([Arber *et al*, 2006](#bib4){ref-type="other"}). However, their use is associated with increased cardiovascular risk ([Baron *et al*, 2006](#bib6){ref-type="other"}; [Bertagnolli *et al*, 2006](#bib7){ref-type="other"}). The treatment of CRC patients with selective COX2 inhibitors should be less effective, because increased COX2 expression is present in the earlier phase of colorectal carcinogenesis ([Eberhart *et al*, 1994](#bib14){ref-type="other"}; [Yona and Arber, 2006](#bib40){ref-type="other"}), but the exact molecular biological reasons in the background of this phenomenon are not clarified yet. High-throughput screening technologies such as mRNA expression microarrays were applied to find other molecular targets of selective COX2 inhibitors besides COX2, in order to discover the mechanisms explaining their anti-cancer effect in prostate cancer ([John-Aryankalayil *et al*, 2009](#bib25){ref-type="other"}; [Sooriakumaran *et al*, 2009](#bib33){ref-type="other"}) and CRC ([Zagani *et al*, 2009](#bib41){ref-type="other"}).

In this study, we analysed the effect of NS398 selective COX2 inhibitor on adenoma- and CRC-associated gene expression profiles in the HT29 colon adenocarcinoma cell line using the whole-genomic HGU133 Plus 2.0 microarray system. The global gene expression modulatory effect of NS398 was also examined to find other target molecules and pathways influenced by NS398 selective COX2 inhibitor treatment in epithelial cells.

We found that NS398 has a reverse effect on the expression of genes with altered expression in the colorectal adenoma--carcinoma sequence. NS398 more efficiently inverted the expression changes at the adenoma than in the carcinoma stage, demonstrating that it is an effective drug in CRC chemoprevention in the early phase of carcinogenesis.

We have previously identified CRC and adenoma-specific gene expression marker sets in biopsy samples for diagnostic classification. Although colorectal adenoma and adenocarcinoma are epithelial alterations, the cancer microenvironment and interaction between cancer and stromal cells have critical roles in tumour development and progression. That is why the origin of mRNA expression changes -- identified in biopsy samples containing both epithelial and stromal tissue elements -- was analysed using LCM epithelial samples before model selection. The HT29 colon adenocarcinoma cell line was selected after establishing the fact that most of the above-mentioned markers are epithelium derived. The other reason was that COX2 is decisively expressed in the adenomatous or tumourous epithelium, but there are several studies in which stromal COX2 expression is reported ([Nakagawa *et al*, 2004](#bib30){ref-type="other"}; [Soumaoro *et al*, 2004](#bib34){ref-type="other"}).

Our gene expression microarray results strengthen the previously published data by which the anti-cancer effect of the selective COX2 inhibitors is mainly due to their anti-proliferative and pro-apoptotic properties ([Guardavaccaro *et al*, 2000](#bib21){ref-type="other"}; [Hung *et al*, 2000](#bib24){ref-type="other"}; [Brown *et al*, 2001](#bib9){ref-type="other"}; [Li *et al*, 2001](#bib28){ref-type="other"}; [Zhang and DuBois, 2001](#bib42){ref-type="other"}; [Nishikawa *et al*, 2004](#bib31){ref-type="other"}; [Chen *et al*, 2009](#bib11){ref-type="other"}; [Sooriakumaran *et al*, 2009](#bib33){ref-type="other"}; [Zagani *et al*, 2009](#bib41){ref-type="other"}). The cell proliferation inhibitory effect of NS398 could be detected in our microarray analysis by causing cell cycle arrest in the G1 phase, as described earlier ([Hung *et al*, 2000](#bib24){ref-type="other"}). This can be mediated not only by p27KIP1 ([Hung *et al*, 2000](#bib24){ref-type="other"}) but also by p18-INK4C (CDKN2C) and CIP2 (CDKN3) overexpression (the latter ones showed more than a 4.5-fold overexpression under NS398 treatment in our study). The p53-inducible gene BTG2 (we found to be 4.6-fold upregulated in HT29 cells after NS398 treatment) also contributes to the anti-proliferative activity of NS398 through its inhibition effect to G(1)--S transition by reduction of cyclin D1 levels ([Guardavaccaro *et al*, 2000](#bib21){ref-type="other"}). The cell proliferation inhibitory effect of NS398 has also been proven in MTT assay.

The inhibition of COX2 by NS398 results in the accumulation of arachidonic acid in cancer cells and, therefore, would trigger apoptosis, but the mechanisms by which NSAIDs induce cancer cells to apoptosis can also be COX2 independent. In this study, a wide range of pro-apoptotic genes in different phases of apoptosis were found to be overexpressed under NS398 treatment including TRAIL death ligand (TNFSF10), SIVA1 death receptor in CD27-induced pathway and molecules involved in the execution phase of apopotosis such as the APAF1 apoptosome protein and CASP6 effector caspase. Death-associated kinase-3 (DAPK3) inducing morphological changes in apoptosis was also upregulated by NS398 in HT29 cells. In accordance with the findings of [Li *et al* (2001](#bib28){ref-type="other"}), NS398-dependent apoptosis in colon cancer cells occurred through a cytochrome *c*-dependent pathway in our experiments. We found that the activation of the p53-dependent pathway can also trigger apoptotic processes via the cytochrome *c* pathway. Overexpression of tumour protein p53-inducible nuclear protein-1 and tumour protein p53-inducible protein-3 pro-apoptotic molecules indicates p53-dependent apoptosis. p73, which can transactivate p53-responsive genes causing cell cycle arrest and apoptosis, is also upregulated under NS398 COX2 inhibitor treatment. Celecoxib also caused overexpression of p73 tumour-suppressor gene in prostate cancer in a randomised controlled phase II pre-surgical trial ([Sooriakumaran *et al*, 2009](#bib33){ref-type="other"}).

Although only few genes involved in angiogenesis showed significant mRNA expression changes, in accordance with observations of [Abdelrahim and Safe (2005)](#bib1){ref-type="other"} and [Huang *et al* (2005](#bib23){ref-type="other"}), we also detected the downregulation of VEGF, one of the most important angiogenic factors, besides the underexpression of others such as PTEN and IL18.

In summary, in this study, we analysed the effect of NS398 selective COX2 inhibitor treatment on colorectal adenoma- and CRC-associated gene expression alterations using whole-genomic mRNA expression microarrays and the HT29 colon adenocarcinoma cell line. Dose-dependent inhibition of COX2 protein expression was found to be associated with reversal gene expression pattern changes in the colorectal normal-adenoma but less in the normal-carcinoma pathway. Our findings can provide a molecular explanation with regard to the efficacy of selective COX2 inhibitors in CRC chemoprevention in the pre-cancerous adenoma phase. Furthermore, our results can give an insight into the global molecular background of selective COX2 inhibitor administration suggesting the involvement of p18-INK4C, CIP2 cyclin-dependent kinase inhibitors and p53-inducible BTG2 gene in NS398-dependent proliferation inhibition and TRAIL- and p53-mediated apoptotic pathways.
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![Functional classification of differentially expressed genes in HT29 cells under NS398 treatment. (**A**) Distribution of differentially expressed transcripts in the main cell functional groups. (**B**) Distribution of downregulated transcripts in the main cell functional groups. (**C**) Distribution of upregulated transcripts in the main cell functional groups.](6605515f1){#fig1}

![Changes in colorectal adenoma and cancer-related mRNA expression patterns under NS398 treatment. (**A**) Expression of adenoma *vs* normal discriminatory genes in biopsy samples and in HT29 colon adenocarcinoma cells under NS398 treatment (**B**). Expression of CRC *vs* normal discriminatory genes in biopsy samples and in HT29 colon adenocarcinoma cells under NS398 treatment.](6605515f2){#fig2}

![The decrease in COX2 protein expression under NS398 treatment. Dose-dependent inhibition of COX2 protein expression was observed under NS398 treatment. Strong granular and/or diffuse cytoplasmatic immunostaining was detected in COX2-positive cells. (**A**) COX2 protein expression in untreated control HT29 cells. (**B**) COX2 protein expression in HT29 cells treated with 100 *μ*[M]{.smallcaps} NS398 ( × 10 magnification, haematoxylin co-staining). (**C**) COX2 protein expression detected by western blot analysis. The diagram shows the band intensities determined by Molecular Imaging Software version 4.0.](6605515f3){#fig3}

###### 

Classificatory genes identified by gene expression microarray analysis of colorectal biopsy samples

  **Affymetrix ID**       **Gene symbol**   **Gene name**                                                        **Function**
  ----------------------- ----------------- -------------------------------------------------------------------- -----------------------------------------------------------------------------
  *Adenoma* vs *normal*                                                                                          
  212942_s\_at            KIAA1199          KIAA1199                                                             Sensory perception of sound
  227475_at               FOXQ1             Forkhead box Q1                                                      Transcription, regulation of transcription
  207504_at               CA7               Carbonic anhydrase VII                                               One-carbon compound metabolic process
  204719_at               ABCA8             ATP-binding cassette, subfamily A (ABC1), member 8                   Transport
  1552296_at              BEST4             Bestrophin 4                                                         Ion transport
  240157_at               ---               ---                                                                  ---
  205861_at               SPIB              Spi-B transcription factor                                           Transcription, regulation of transcription
  207080_s\_at            PYY               Peptide YY                                                           Cell motility, cytoskeleton organisation and biogenesis, cell proliferation
  237530_at               ---               ---                                                                  ---
  230204_at               HAPLN1            Hyaluronan and proteoglycan link protein 1                           Cell adhesion
  240389_at               TRPM6             Transient receptor potential cation channel, subfamily M, member 6   Protein amino acid phosphorylation, calcium ion transport
  1558324_a\_at           TMEM72            Transmembrane protein 72                                             ---
  214598_at               CLDN8             Claudin 8                                                            Calcium-independent cell--cell adhesion
  203256_at               CDH3              Cadherin 3, type 1, P-cadherin                                       Transcription, regulation of transcription
  205523_at               HAPLN1            Hyaluronan and proteoglycan link protein 1                           Cell adhesion
  206422_at               GCG               Glucagon                                                             Signal transduction, feeding behavior, cell proliferation
  213921_at               SST               Somatostatin                                                         Cell surface receptor linked signal transduction
  224412_s\_at            TRPM6             Transient receptor potential cation channel, subfamily M, member 6   Protein amino acid phosphorylation, calcium ion transport
  203000_at               STMN2             Stathmin-like 2                                                      Intracellular signalling cascade, neuron differentiation
  202504_at               TRIM29            Tripartite motif-containing 29                                       Transcription from RNA polymerase II promoter
                                                                                                                  
  *CRC* vs *normal*                                                                                               
  202112_at               VWF               von Willebrand factor                                                Cell adhesion, blood coagulation, hemostasis
  202859_x\_at            IL8               Interleukin 8                                                        Angiogenesis, cell motility, chemotaxis
  209395_at               CHI3L1            Chitinase 3-like 1                                                   Carbohydrate metabolic process, chitin catabolic process, transport
  202917_s\_at            S100A8            S100 calcium binding protein A8                                      Inflammatory response
  218468_s\_at            GREM1             Gremlin 1, cysteine knot superfamily, homolog                        Multicellular organismal development, nervous system development
  212531_at               LCN2              Lipocalin 2                                                          Transport
  204470_at               CXCL1             Chemokine (C-X-C motif) ligand 1                                     Chemotaxis, inflammatory response, cell proliferation
  211981_at               COL4A1            Collagen, type IV, *α*1                                              Phosphate transport
  213338_at               TMEM158           Transmembrane protein 158                                            ---
  211980_at               COL4A1            Collagen, type IV, *α*1                                              Phosphate transport
  209752_at               REG1A             Regenerating islet-derived 1*α*                                      Positive regulation of cell proliferation
  211959_at               IGFBP5            Insulin-like growth factor binding protein 5                         Regulation of cell growth, signal transduction
  225681_at               CTHRC1            Collagen triple helix repeat containing 1                            Phosphate transport
  218469_at               GREM1             Gremlin 1, cysteine knot superfamily, homolog                        Multicellular organismal development, nervous system development
  209087_x\_at            MCAM              Melanoma cell adhesion molecule                                      Cell adhesion, anatomical structure morphogenesis
  207504_at               CA7               Carbonic anhydrase VII                                               One-carbon compound metabolic process
  205067_at               IL1B              Interleukin 1, *β*                                                   Angiogenesis, fever, apoptosis, inflammatory response
  212657_s\_at            IL1RN             Interleukin 1 receptor antagonist                                    Inflammatory response, immune response
  225664_at               COL12A1           Collagen, type XII, *α*1                                             Skeletal development, phosphate transport, cell adhesion
  202311_s\_at            COL1A1            Collagen, type I, *α*1                                               Skeletal development, ossification, phosphate transport
  209774_x\_at            CXCL2             Chemokine (C-X-C motif) ligand 2                                     Chemotaxis, inflammatory response
  225842_at               PHLDA1            Pleckstrin homology-like domain, family A, member 1                  Apoptosis, FasL biosynthetic process
  219727_at               DUOX2             Dual oxidase 2                                                       Electron transport, response to oxidative stress
  211506_s\_at            IL8               Interleukin 8                                                        Angiogenesis, cell motility, chemotaxis, inflammatory response
  209875_s\_at            SPP1              Secreted phosphoprotein 1 (osteopontin)                              Ossification, cell adhesion, negative regulation of bone mineralisation
  205828_at               MMP3              Matrix metallopeptidase 3                                            Proteolysis, metabolic process
  211340_s\_at            MCAM              Melanoma cell adhesion molecule                                      Cell adhesion, anatomical structure morphogenesis
  1552296_at              BEST4             Bestrophin 4                                                         Ion transport
  204677_at               CDH5              Cadherin 5, type 2, VE-cadherin                                      Cell adhesion
  202404_s\_at            COL1A2            Collagen, type I, *α*2                                               Skeletal development, phosphate transport
  240157_at               ---               ---                                                                  ---
  39402_at                IL1B              Interleukin 1, *β*                                                   Angiogenesis, fever, apoptosis, inflammatory response
  206121_at               AMPD1             Adenosine monophosphate deaminase 1                                  Nucleotide metabolic process
  201438_at               COL6A3            Collagen, type VI, *α*3                                              Phosphate transport, cell adhesion, muscle development
  201195_s\_at            SLC7A5            Solute carrier family 7, member 5                                    Amino acid metabolic process, transport
  1558324_a\_at           TMEM72            Transmembrane protein 72                                             ---
  210869_s\_at            MCAM              Melanoma cell adhesion molecule                                      Cell adhesion, anatomical structure morphogenesis
  220724_at               FLJ21511          Hypothetical protein FLJ21511                                        ---

###### 

Taqman validation of 12 selected discriminatory genes

  **Taqman ID**   **Gene symbol**   **Gene name**                                                        **Affymetrix ID**   **Compared sample groups**   **Fold change on microarrays**   **Fold change in RT--PCR 2**^**(-**ΔΔ**CT)**^   ***P*-value**
  --------------- ----------------- -------------------------------------------------------------------- ------------------- ---------------------------- -------------------------------- ----------------------------------------------- ---------------
  Hs00200350_m1   ABCA8             ATP-binding cassette, subfamily A (ABC1), member 8                   204719_at           Adenoma *vs* normal          0.078                            0.10                                            **0.00061**
  Hs00214306_m1   TRPM6             Transient receptor potential cation channel, subfamily M, member 6   240389_at           Adenoma *vs* normal          0.086                            0.04                                            **0.00006**
  Hs00169795_m1   VWF               von Willebrand factor                                                202112_at           CRC *vs* normal              3.61                             12.21                                           0.55142
  Hs00174103_m1   IL8               Interleukin 8                                                        202859_x\_at        CRC *vs* normal              20.20                            148.06                                          **0.00283**
  Hs00194353_m1   LCN2              Lipocalin 2                                                          212531_at           CRC *vs* normal              7.97                             28.44                                           **0.00051**
  Hs00236937_m1   CXCL1             Chemokine (C-X-C motif) ligand 1                                     204470_at           CRC *vs* normal              13.10                            14.32                                           **0.01140**
  Hs00266237_m1   COL4A1            Collagen, type IV, *α*1                                              211980_at           CRC *vs* normal              5.21                             10.41                                           **0.02831**
  Hs00174838_m1   MCAM              Melanoma cell adhesion molecule                                      209087_x\_at        CRC *vs* normal              2.92                             6.87                                            0.05209
  Hs00277299_m1   IL1RN             Interleukin 1 receptor antagonist                                    212657_s\_at        CRC *vs* normal              11.99                            25.28                                           **0.00714**
  Hs00236966_m1   CXCL2             Chemokine (C-X-C motif) ligand 2                                     209774_x\_at        CRC *vs* normal              9.20                             13.00                                           **0.00204**
  Hs00204187_m1   DUOX2             Dual oxidase 2                                                       219727_at           CRC *vs* normal              9.70                             30.06                                           **0.00363**
  Hs00167093_m1   SPP1              Secreted phosphoprotein 1 (osteopontin)                              209875_s\_at        CRC *vs* normal              8.92                             12.55                                           0.07492

*P*-value represents the correlation to the microarray data. The significant different expression (*P*\<0.05) is marked in bold.

[^1]: These authors contributed equally to this work.
